{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:38:04Z","timestamp":1777927084733,"version":"3.51.4"},"reference-count":11,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Perit Dial Int"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Intraperitoneal (IP) vancomycin is recommended as one of the treatment options for gram-positive coverage in the management of peritoneal dialysis (PD)-associated peritonitis. There is a lack of literature supporting the optimal dose and approach to vancomycin therapeutic drug-level monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A retrospective chart review was conducted using the BC Renal Agency PROMIS Database and our hospital records from 1 June 2011 to 1 July 2019. Adult patients with PD-associated peritonitis who received IP vancomycin and had at least one serum vancomycin level drawn were included. All patients received a loading dose of 30 mg\/kg, which was repeated every 3\u20135 days depending on PD modality. Serum vancomycin levels were drawn prior to the second vancomycin dose, then at the discretion of the prescriber. The primary end point was the rate of therapeutic serum vancomycin levels \u226515 mg\/L.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Twenty-three episodes of PD-associated peritonitis in 20 patients met the eligibility criteria. Only 15\/23 serum vancomycin levels were drawn appropriately after the first dose. Sixty per cent of these levels were subtherapeutic at &lt;15 mg\/L. All subsequent serum vancomycin levels were above the therapeutic target. Most peritonitis episodes (78%) achieved resolution of infection. Residual kidney function was not significantly correlated with serum vancomycin levels ( p = 0.19).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>An IP vancomycin regimen of 30 mg\/kg every 3\u20135 days resulted in subtherapeutic serum vancomycin levels in most patients following the loading dose but therapeutic levels thereafter. A large percentage of vancomycin levels were drawn inappropriately due to misalignment of outpatient follow-up visits and timing of blood work.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/08968608211051579","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T23:36:58Z","timestamp":1634859418000},"page":"171-176","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of intraperitoneal vancomycin in peritoneal dialysis-associated peritonitis"],"prefix":"10.1177","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1403-3730","authenticated-orcid":false,"given":"Wui Ming","family":"Chang","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Vancouver General Hospital, Vancouver, British Columbia, Canada"},{"name":"Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Vancouver General Hospital, Vancouver, British Columbia, Canada"},{"name":"Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Shalansky","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Vancouver General Hospital, Vancouver, British Columbia, Canada"},{"name":"Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suneet R","family":"Singh","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Vancouver General Hospital, Vancouver, British Columbia, Canada"},{"name":"Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,10,21]]},"reference":[{"key":"bibr1-08968608211051579","doi-asserted-by":"publisher","DOI":"10.3747\/pdi.2016.00078"},{"key":"bibr2-08968608211051579","first-page":"3722","volume-title":"Applied therapeutics: the clinical use of drugs. 11th ed","author":"Wang SK","year":"2018"},{"key":"bibr3-08968608211051579","first-page":"CD005284","volume":"4","author":"Ballinger AE","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr4-08968608211051579","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-445"},{"key":"bibr5-08968608211051579","doi-asserted-by":"publisher","DOI":"10.1016\/0272-6386(95)90132-9"},{"key":"bibr6-08968608211051579","doi-asserted-by":"publisher","DOI":"10.3747\/pdi.2010.00049"},{"key":"bibr7-08968608211051579","doi-asserted-by":"publisher","DOI":"10.3747\/pdi.2013.00156"},{"key":"bibr8-08968608211051579","doi-asserted-by":"publisher","DOI":"10.3747\/pdi.2010.00294"},{"key":"bibr9-08968608211051579","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfm079"},{"key":"bibr10-08968608211051579","unstructured":"Clinical & Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing.\n                      28th ed. CLSI supplement M100\n                      . Wayne, PA: Clinical and Laboratory Standards Institute, 2018, p. 59."},{"key":"bibr11-08968608211051579","doi-asserted-by":"publisher","DOI":"10.1177\/0896860819889774"}],"container-title":["Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08968608211051579","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08968608211051579","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08968608211051579","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:34:37Z","timestamp":1777674877000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08968608211051579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,21]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1177\/08968608211051579"],"URL":"https:\/\/doi.org\/10.1177\/08968608211051579","relation":{},"ISSN":["0896-8608","1718-4304"],"issn-type":[{"value":"0896-8608","type":"print"},{"value":"1718-4304","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,21]]}}}